Investment in SymBio Pharmaceuticals by the affiliate of Heights Capital Management through third party allotment

Lawyers

Period

May, 2022

Practices

Capital Markets

People

Katsumasa Suzuki

Katsumasa Suzuki

Partner

Tokyo

+81-3-6212-8327

katsumasa.suzuki@morihamada.com

M&A

Corporate Law

Capital Markets

Crisis Management / Compliance
Masakazu Kumagai

Masakazu Kumagai

Partner

Tokyo

+81-3-6266-8522

masakazu.kumagai@morihamada.com

M&A

Corporate Law

Capital Markets

Related Cases

April, 2025

Privatization of AEON MALL

Katsumasa Suzuki

Takafumi Goto
March, 2025

Privatization of NAIGAI TRANS LINE by IA Partners

Katsumasa Suzuki

Masaaki Hirota
March, 2025

Report on the Study Results on the Diversification of Investment Assets by Investment Corporations in the “Study Group on the Future of the Infrastructure Fund Market” at the Tokyo Stock Exchange

Masanori Sato

Shigeki Okatani

Masahito Saeki

Ryosuke Onobori

Makoto Aoyagi
March, 2025

Transfer of shares in AEON Allianz Life Insurance by AEON Financial Service, and conclusion of comprehensive partnership agreement among AEON, AEON Financial Service, and Meiji Yasuda Life Insurance Company

Tomoya Fujita

Kazuo Yoshida

Tetsuya Tamura

Katsumasa Suzuki
March, 2025

TRIAL Holdings’s full acquisition of Seiyu

Katsumasa Suzuki

Akira Matsushita
February, 2025

Secondary offering of common stock of Japan Post Bank

Katsumasa Suzuki

Masakazu Kumagai

Tetsuya Tamura

Go back to Cases

My Page

Mori Hamada My Page
(Members' Portal)

The firm's “Mori Hamada My Page” service enables gathering and viewing of information on seminars, newsletters, publications, public announcements from government agencies, and other matters all in one centralized portal.

Mori Hamada My Page

Lawyers

Find lawyers and professionals

Investment in SymBio Pharmaceuticals by the affiliate of Heights Capital Management through third party allotment​

People

Related Cases

My Page

Search by Alphabetical Order

ABC

Filter by Practices

Filter by Position

Filter by Office/Location

Japan

China

ASEAN Member States

North America

Filter by Supported Language

Investment in SymBio Pharmaceuticals by the affiliate of Heights Capital Management through third party allotment